- Record: found
- Abstract: not found
- Article: not found
Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
G. Jerusalem ,
G. Mariani ,
E.M. Ciruelos ,
M. Martin ,
V.C.G. Tjan-Heijnen ,
P. Neven ,
J.G. Gavila ,
A. Michelotti ,
F. Montemurro ,
D. Generali ,
E. Simoncini ,
I. Lang ,
J. Mardiak ,
B. Naume ,
M. Camozzi ,
K. Lorizzo ,
S. Bianchetti ,
P. Conte
September 2016
September 2016
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
This European phase IIIb, expanded-access multicenter trial evaluated the safety of
EVE plus EXE in a patient population similar to BOLERO-2.